pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 26·1 min read
save

Profit motive highlighted as key to advancing women’s health research and boosting economic productivity

Aug 26, 2026·read at STAT ↗Neutral

Experts say that turning to the profit motive could spur investment in under‑funded women’s health areas such as endometriosis, osteoporosis and autoimmune disorders.

They note a long history of research neglect and warn that federal funding is becoming increasingly precarious, prompting advocates, academics and industry leaders to push market incentives as a new driver.

A 2024 World Economic Forum report cited in the article estimates that fully addressing women’s health gaps could add about $1 trillion to global economic productivity each year by 2040, translating to roughly $300 billion in recovered U.S. productivity.

The piece argues that highlighting the economic upside may persuade companies to allocate more resources toward women’s health research, framing the issue as both a moral and financial opportunity.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: When it comes to women’s health, money talks”

read at STAT ↗
388 words · retrieved Aug 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LEADING2
topics
Cardiology4Endocrinology & Metabolism2Immunology2OncologyWomen's Health

related stories

  • 15h agoCaribou layoffs could wipe out 90% of staffBioSpace
  • Sep 11This week in charts: RA’s insatiable appetite, Novartis’ big slide and a reverse merger spreeBioPharma Dive
  • Aug 31A winner, a loser, and a mid-stage signal from a major cardiology research conferenceSTAT
  • Jul 30New funding, new jobs: 4 biotechs hiring after series B raisesBioSpace
  • Jul 8Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study saysSTAT